{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T17:26:38Z","timestamp":1649006798094},"reference-count":10,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,11,1]]},"DOI":"10.2169\/internalmedicine.0397-17","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T18:25:26Z","timestamp":1528223126000},"page":"3153-3155","source":"Crossref","is-referenced-by-count":1,"title":["Ceritinib Treatment for Carcinomatous Meningitis with a Secondary Mutation at I1171T in Anaplastic Lymphoma Kinase"],"prefix":"10.2169","volume":"57","author":[{"given":"Hironori","family":"Ashinuma","sequence":"first","affiliation":[{"name":"Division of Respiratory Medicine, Chiba Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Shingyoji","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Chiba Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzo","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Division of Neurological Surgery, Chiba Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sana","family":"Yokoi","sequence":"additional","affiliation":[{"name":"Division of Translational Genomics, Chiba Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Chiba Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov 7: 137-155, 2017.","DOI":"10.1158\/2159-8290.CD-16-1123"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Lin YT, Yu CJ, Yang JC, Shih JY. Anaplastic lymphoma kinase (ALK) kinase domain mutation following ALK inhibitor (s) failure in advanced ALK positive non-small-cell lung cancer: analysis and literature review. Clin Lung Cancer 17: e77-e94, 2016.","DOI":"10.1016\/j.cllc.2016.03.005"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Katayama R, Friboulet L, Koike S, et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 20: 5686-5696, 2014.","DOI":"10.1158\/1078-0432.CCR-14-1511"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ou SH, Klempner SJ, Greenbowe JR, et al. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N\/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. J Thorac Oncol 9: 1821-1825, 2014.","DOI":"10.1097\/JTO.0000000000000368"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Toyokawa G, Hirai F, Inamasu E, et al. Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib. J Thorac Oncol 9: e86-e87, 2014.","DOI":"10.1097\/JTO.0000000000000358"},{"key":"6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.lungcan.2015.02.005","volume":"88","author":"SH Ou","year":"2015","unstructured":"6. Ou SH, Greenbowe J, Khan ZU, et al. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Lung Cancer 88: 231-234, 2015.","journal-title":"Lung Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.lungcan.2015.09.006","volume":"91","author":"SH Ou","year":"2016","unstructured":"7. Ou SH, Milliken JC, Azada MC, Miller VA, Ali SM, Klempner SJ. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression. Lung Cancer 91: 70-72, 2016.","journal-title":"Lung Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Li YS, Jiang BY, Yang JJ, et al. Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol 11: 1962-1969, 2016.","DOI":"10.1016\/j.jtho.2016.06.029"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Bui N, Woodward B, Johnson A, Husain H. Novel treatment strategies for brain metastases in non-small-cell lung cancer. Curr Treat Options Oncol 17: 25, 2016.","DOI":"10.1007\/s11864-016-0400-x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ni Z, Zhang TC. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer. J Mol Model 21: 175, 2015.","DOI":"10.1007\/s00894-015-2716-z"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/21\/57_0397-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,3]],"date-time":"2018-11-03T01:14:23Z","timestamp":1541207663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/21\/57_0397-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":10,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0397-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,1]]}}}